Biofilm and the Chronic Inflammatory Loop: Why Some Wounds Stay Open
How biofilm sustains the self-reinforcing inflammatory state that keeps wounds open.
By Ned Swanson, MD, President & Chief Medical Officer, PolarityBio
As discussed in previous blogs (www.polaritybio.com/polarity-blog), chronic wounds are typically stuck in the inflammatory phase, and a large part of what holds them there is biofilm. That pattern holds across the wounds we see most often: diabetic foot ulcers, venous leg ulcers, and pressure ulcers.[1] In the study that first put numbers to this, biofilm structures were found in 60% of chronic wound biopsies and in only 6% of acute wound biopsies.[1] A later systematic review and meta-analysis put the prevalence in chronic wounds at 78.2%.[2] Whichever figure you anchor to, the conclusion is the same: in a wound that will not close, biofilm is closer to the rule than the exception.
What matters clinically is what biofilm does once it's there. It changes how the wound behaves — and it does that by pushing the host into an inflammatory state that feeds itself.
What Is Biofilm?
A biofilm is a structured community of microorganisms encased in a self-produced polymeric matrix. That matrix shields the organisms inside from the host immune response and from antimicrobials, so biofilm-associated bacteria can tolerate drug concentrations that would clear the same organisms living as free-floating cells.[3] The body does recognize it as a threat and mounts a response. It just can't finish the job.
The Reinforcement Loop
Normal healing moves through overlapping phases: hemostasis first, then inflammation, then proliferation, then remodeling. Inflammation is meant to be self-limiting. It clears the threat, then resolves so that rebuilding can begin. Biofilm interrupts that sequence.
Because the immune system cannot clear the biofilm, it keeps recruiting more inflammatory cells. Chronic wounds carry a sustained, elevated burden of neutrophils and macrophages, on the order of two to three times the accumulation seen in healing tissue, along with correspondingly elevated pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β).[3] Those cells release reactive oxygen species and a heavy load of proteases, and they cast neutrophil extracellular traps.[4]
In an acute wound, that process is protective and brief. In a biofilm-laden wound, it runs continuously, and it turns on the wound itself. The excess proteases degrade the extracellular matrix and the growth factors that healing depends on, while the tissue inhibitors that would normally restrain those proteases are suppressed.[4] Reactive oxygen species and trapped neutrophil products add to the tissue damage.[4] The wound stays locked in the inflammatory phase and never advances to building new tissue.[3]
And here's the part that makes this a loop and not just a delay. The biofilm survives, so the stimulus never goes away. On top of that, the damage from that inflammatory “attack” degrades the tissue and the signaling that the wound needs to move forward. So, the host keeps attacking a target it can't remove, which damages the wound bed, and the persisting biofilm keeps the attack running.
A biofilm-laden wound is not waiting to heal. It is being actively held open by the response meant to heal it.
Nowhere is this loop less forgiving than in the diabetic foot ulcer. Neuropathy delays presentation, so by the time anyone sees the wound it's usually well established. Vascular insufficiency and local tissue hypoxia sustain the inflammatory drive rather than resolve it.[3] And in diabetic, biofilm-containing wounds, the neutrophil response itself is blunted, so the cells showing up in excess are also worse at the job they came to do.[4] You end up with a wound paying the full inflammatory cost of the loop and getting none of the benefit.
Why “Treat the Infection” Is Not the Same Problem
This is also why a biofilm-driven wound doesn't behave like the infection you think you're treating. Systemic antibiotics are typically dosed against free-floating bacteria, and biofilm organisms tolerate concentrations well above what those regimens deliver.[3] Clearing whatever a culture happened to catch today does nothing about the structure that will regenerate it tomorrow. The problem isn't just which organisms are there. It's that they're living inside a matrix built to keep them safe.
Breaking the Loop
If the loop keeps feeding itself, then breaking it must be physical — and it has to be repeated. Consensus guidance centers on disrupting the biofilm mechanically through debridement, then acting inside the short window that disruption opens.[5] Debridement never gets all of it, and what's left comes back fast. Mature, tolerant biofilm can re-establish in roughly 24 to 72 hours.[5] That's days, not weeks. That biology is the rationale for maintenance debridement and biofilm-based wound care rather than a single debridement. It also defines the endpoint: biofilm must be cleared and kept cleared up to the point of definitive closure. Autologous reconstruction of any kind is the first step toward that definitive closure. Removing the biofilm also removes the stimulus for the inflammatory loop, which is what lets the wound shift out of the inflammatory phase and back onto a healing trajectory.
Breaking the loop is necessary. It isn't the whole job. A wound that's been held open for months has already lost extracellular matrix and growth factor signaling to the proteases described above, and debridement and biofilm control only remove what was blocking repair. They don't rebuild what's already gone. Closing that gap is the case for advanced wound care, and specifically for autologous reconstruction approaches that rebuild the tissue architecture rather than only cover the defect. That reconstruction is what moves a wound from controlled to definitively closed.
So, here's the reframe worth carrying into clinic. In a wound that won't close, chronic inflammation usually isn't a background condition you manage around. It's the disease process itself, sustained by a biofilm the body can't clear on its own. The wound will not move forward until that loop is broken, and it will not stay broken unless the biofilm is kept from rebuilding through to definitive closure, with autologous reconstruction as a potential first step in getting there.
References
James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen. 2008;16(1):37–44. doi:10.1111/j.1524-475X.2007.00321.x.
Malone M, Bjarnsholt T, McBain AJ, et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017;26(1):20–25. doi:10.12968/jowc.2017.26.1.20.
Razdan K, Garcia-Lara J, Sinha VR, Singh KK. Pharmaceutical strategies for the treatment of bacterial biofilms in chronic wounds. Drug Discov Today. 2022;27(8):2137–2150. doi:10.1016/j.drudis.2022.04.020.
Versey Z, da Cruz Nizer WS, Russell E, et al. Biofilm-innate immune interface: contribution to chronic wound formation. Front Immunol. 2021;12:648554. doi:10.3389/fimmu.2021.648554.
Schultz G, Bjarnsholt T, James GA, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744–757. doi:10.1111/wrr.12590.
